Phase 2, multi-center, randomized, double-blind, placebo-controlled, 3 arm, 12-month study to evaluate the effects of GPI 1485 on erectile function in patients undergoing bilateral nerve-sparing radical retropubic prostatectomy for prostatic carcinoma
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2009
At a glance
- Drugs GM 1485 (Primary)
- Indications Erectile dysfunction
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 05 Nov 2008 Sponsor and affiliate changed from MGI Pharma to Eisai Medical Research, based on information from ClinicalTrials.gov.
- 21 Apr 2008 Status changed from in progress to completed, from clinicaltrials.gov record.
- 18 Dec 2005 New trial record.